Amitriptyline-Induced Rabbit Syndrome: A Case of Refractory Oral Vertical Dyskinesia
Objective: We present a case of refractory rabbit syndrome associated with the use of amitriptyline, a tricyclic antidepressant, highlighting both the diagnostic and therapeutic challenges…Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease
Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…Comparison of Age, Cognitive, Autonomic, and Motor Testing between Serotonergic vs Idiopathic REM-Sleep Behavior Disorder
Objective: To compare the age, cognitive, autonomic, and motor function of REM-Sleep Behavior Disorder (RBD) patients amongst those who believe their symptoms were triggered by…Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder
Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major…Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia
Objective: This study evaluates neuropsychiatric comorbidity in spinocerebellar ataxia (SCA) and highlights key aspects of management in the geriatric population. It discusses efficacy of neuropsychotropic…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder
Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative
Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…
- 1
- 2
- 3
- 4
- Next Page »